Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Lomitapide | The metabolism of Lomitapide can be decreased when combined with Dapoxetine. |
| Cyproheptadine | The therapeutic efficacy of Dapoxetine can be decreased when used in combination with Cyproheptadine. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Dapoxetine is combined with Desmopressin. |
| Ioflupane I-123 | Dapoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dapoxetine. |
| Metyrosine | The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Dapoxetine. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Dapoxetine is combined with Pimozide. |
| Ramipril | Dapoxetine may increase the orthostatic hypotensive activities of Ramipril. |
| Fosinopril | Dapoxetine may increase the orthostatic hypotensive activities of Fosinopril. |
| Trandolapril | Dapoxetine may increase the orthostatic hypotensive activities of Trandolapril. |
| Benazepril | Dapoxetine may increase the orthostatic hypotensive activities of Benazepril. |
| Enalapril | Dapoxetine may increase the orthostatic hypotensive activities of Enalapril. |
| Moexipril | Dapoxetine may increase the orthostatic hypotensive activities of Moexipril. |
| Lisinopril | Dapoxetine may increase the orthostatic hypotensive activities of Lisinopril. |
| Perindopril | Dapoxetine may increase the orthostatic hypotensive activities of Perindopril. |
| Quinapril | Dapoxetine may increase the orthostatic hypotensive activities of Quinapril. |
| Omapatrilat | Dapoxetine may increase the orthostatic hypotensive activities of Omapatrilat. |
| Rescinnamine | Dapoxetine may increase the orthostatic hypotensive activities of Rescinnamine. |
| Captopril | Dapoxetine may increase the orthostatic hypotensive activities of Captopril. |
| Cilazapril | Dapoxetine may increase the orthostatic hypotensive activities of Cilazapril. |
| Spirapril | Dapoxetine may increase the orthostatic hypotensive activities of Spirapril. |
| Temocapril | Dapoxetine may increase the orthostatic hypotensive activities of Temocapril. |
| Enalaprilat | Dapoxetine may increase the orthostatic hypotensive activities of Enalaprilat. |
| Imidapril | Dapoxetine may increase the orthostatic hypotensive activities of Imidapril. |
| Zofenopril | Dapoxetine may increase the orthostatic hypotensive activities of Zofenopril. |
| Delapril | Dapoxetine may increase the orthostatic hypotensive activities of Delapril. |
| Benazeprilat | Dapoxetine may increase the orthostatic hypotensive activities of Benazeprilat. |
| Fosinoprilat | Dapoxetine may increase the orthostatic hypotensive activities of Fosinoprilat. |
| Ramiprilat | Dapoxetine may increase the orthostatic hypotensive activities of Ramiprilat. |
| Trandolaprilat | Dapoxetine may increase the orthostatic hypotensive activities of Trandolaprilat. |
| Moexiprilat | Dapoxetine may increase the orthostatic hypotensive activities of Moexiprilat. |
| Perindoprilat | Dapoxetine may increase the orthostatic hypotensive activities of Perindoprilat. |
| Quinaprilat | Dapoxetine may increase the orthostatic hypotensive activities of Quinaprilat. |
| Cilazaprilat | Dapoxetine may increase the orthostatic hypotensive activities of Cilazaprilat. |
| Buprenorphine | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Dapoxetine. |
| Hydrocodone | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Magnesium sulfate | The therapeutic efficacy of Dapoxetine can be increased when used in combination with Magnesium sulfate. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Orphenadrine | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Pramipexole | Dapoxetine may increase the sedative activities of Pramipexole. |
| Ropinirole | Dapoxetine may increase the sedative activities of Ropinirole. |
| Rotigotine | Dapoxetine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dapoxetine. |
| Sodium oxybate | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Thalidomide | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dapoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Dapoxetine. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Dapoxetine. |
| Tadalafil | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Tadalafil. |
| Vardenafil | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Vardenafil. |
| Dipyridamole | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Dipyridamole. |
| Ibudilast | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Ibudilast. |
| Avanafil | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Avanafil. |
| Udenafil | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Udenafil. |
| Doxofylline | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Doxofylline. |
| Mirodenafil | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Mirodenafil. |
| Fostamatinib | The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Fostamatinib. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Dapoxetine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Dapoxetine. |
| Fentanyl | The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Dapoxetine. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Dapoxetine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Dapoxetine. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Dapoxetine. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Dapoxetine. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Dapoxetine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dapoxetine. |
| Dihydroergotamine | Dapoxetine may increase the orthostatic hypotensive activities of Dihydroergotamine. |
| Olanzapine | Dapoxetine may increase the orthostatic hypotensive activities of Olanzapine. |
| Clozapine | The serum concentration of Clozapine can be increased when it is combined with Dapoxetine. |
| Promazine | Dapoxetine may increase the orthostatic hypotensive activities of Promazine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine. |
| Prazosin | Dapoxetine may increase the orthostatic hypotensive activities of Prazosin. |
| Imipramine | Dapoxetine may increase the orthostatic hypotensive activities of Imipramine. |
| Chlorpromazine | Dapoxetine may increase the orthostatic hypotensive activities of Chlorpromazine. |
| Nortriptyline | Dapoxetine may increase the orthostatic hypotensive activities of Nortriptyline. |
| Amoxapine | Dapoxetine may increase the orthostatic hypotensive activities of Amoxapine. |
| Doxazosin | Dapoxetine may increase the orthostatic hypotensive activities of Doxazosin. |
| Labetalol | Dapoxetine may increase the orthostatic hypotensive activities of Labetalol. |
| Nicardipine | Dapoxetine may increase the orthostatic hypotensive activities of Nicardipine. |
| Verapamil | The metabolism of Dapoxetine can be decreased when combined with Verapamil. |
| Phentolamine | Dapoxetine may increase the orthostatic hypotensive activities of Phentolamine. |
| Ergotamine | Dapoxetine may increase the orthostatic hypotensive activities of Ergotamine. |
| Nicergoline | Dapoxetine may increase the orthostatic hypotensive activities of Nicergoline. |
| Tamsulosin | Dapoxetine may increase the orthostatic hypotensive activities of Tamsulosin. |
| Trimipramine | Dapoxetine may increase the orthostatic hypotensive activities of Trimipramine. |
| Risperidone | Dapoxetine may increase the orthostatic hypotensive activities of Risperidone. |
| Propiomazine | Dapoxetine may increase the orthostatic hypotensive activities of Propiomazine. |
| Tolazoline | Dapoxetine may increase the orthostatic hypotensive activities of Tolazoline. |
| Trifluoperazine | Dapoxetine may increase the orthostatic hypotensive activities of Trifluoperazine. |
| Flupentixol | Dapoxetine may increase the orthostatic hypotensive activities of Flupentixol. |
| Quinidine | Dapoxetine may increase the orthostatic hypotensive activities of Quinidine. |
| Phenoxybenzamine | Dapoxetine may increase the orthostatic hypotensive activities of Phenoxybenzamine. |